81 Biggest Movers From Yesterday
Gainers Rail Vision Ltd. (NASDAQ: RVSN ) shares climbed 62.4% to close at $2.16 on Wednesday after gaining around 5% on Tuesday. TransMedics Group, Inc. (NASDAQ: TMDX ) jumped 40.3% to close at $30.69 after better than expected Q1 earnings and 2022 guidance. Aclarion, Inc. (NASDAQ: ACON ) jumped 36.6% to settle at $2.35 after declining over 5% on Tuesday. The company had its IPO on April 22. Alaunos Therapeutics, Inc. (NASDAQ: TCRT ) jumped 36% to settle at $0.7547 after jumping around 13% on Tuesday. Bright Health Group, Inc. (NYSE: BHG ) gained 33.3% to close at $2.24 after the company reported better-than-expected Q1 sales results and reaffirmed FY22 guidance. Super Micro Computer, Inc. (NASDAQ: SMCI ) climbed 31.2% to settle at $30.69 after the company reported better-than-expected Q3 EPS and sales results and raised Q4 guidance. Livent Corporation (NYSE: LTHM ) gained 30.3% to close at $28.55 after the company reported better-than-expected Q1 results and raised FY22 guidance. AIkido Pharma Inc. (NASDAQ: AIKI ) jumped 30.1% to settle at $0.4622.
81 Biggest Movers From Yesterday
Gainers Rail Vision Ltd. (NASDAQ: RVSN ) shares climbed 62.4% to close at $2.16 on Wednesday after gaining around 5% on Tuesday. TransMedics Group, Inc. (NASDAQ: TMDX ) jumped 40.3% to close at $30.69 after better than expected Q1 earnings and 2022 guidance. Aclarion, Inc. (NASDAQ: ACON ) jumped 36.6% to settle at $2.35 after declining over 5% on Tuesday. The company had its IPO on April 22. Alaunos Therapeutics, Inc. (NASDAQ: TCRT ) jumped 36% to settle at $0.7547 after jumping around 13% on Tuesday. Bright Health Group, Inc. (NYSE: BHG ) gained 33.3% to close at $2.24 after the company reported better-than-expected Q1 sales results and reaffirmed FY22 guidance. Super Micro Computer, Inc. (NASDAQ: SMCI ) climbed 31.2% to settle at $30.69 after the company reported better-than-expected Q3 EPS and sales results and raised Q4 guidance. Livent Corporation (NYSE: LTHM ) gained 30.3% to close at $28.55 after the company reported better-than-expected Q1 results and raised FY22 guidance. AIkido Pharma Inc. (NASDAQ: AIKI ) jumped 30.1% to settle at $0.4622.